Researchers developed and validated a new genomic microarray test that identifies whether a tumor’s growth is fueled by the female hormone estrogen and the role of a growth factor receptor known as HER-2 that makes a tumor vulnerable to a specific drug. The status of these factors is now determined by pathology tests.
About 70 percent of breast cancers are estrogen-receptor positive and another 15 to 25 percent are human epidermal growth factor receptor-2 (HER-2) positive. Each receptor status requires different types of treatment.
Read the complete article that talkes about the revolutionary test that promises to chage the way cancer is treated
Filed under: Affymetrix, bioinformatics, cancer, cancer microarray, clinical diagnostics, clinical microarray, custom microarray, drug development, drug discoverry, gene expression, genetics, genotyping, Hormone replacement and Genetics, hormone replacement therapy, microarray, microarray for clinical diagnostics, Pharmacogenomics | Leave a comment »